Quest Diagnostics Inc.
- DGX ยท NYSE
- Services-Medical Laboratories
- Secaucus, NJ
- 57,000 employees
- CIK 0001022079
Updated from SEC filings through
Top things to know
Executives
- Jim Davis Chairman, CEO and President 8-K, 2026-10-22
- J. E. Davis CEO and President 4, 2026-09-03
-
Sam Samad Executive Vice President & CFO 4, 2026-07-27 - Sam A. Samad Executive Vice President and Chief Financial Officer 10-K, 2026-02-26
-
Mark E. Delaney SVP & Chief Commercial Officer 4, 2026-07-29 -
Catherine T. Doherty Executive Vice President 4, 2026-03-06
What leadership is saying
“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI”
Earnings press release (8-K Ex. 99.1), filed October 22, 2026
Quest Diagnostics Inc is a U.S. public company in services-medical laboratories (SIC 8071), headquartered in Secaucus, NJ. It trades as DGX on NYSE. Revenue was $11.0B in the fiscal year ending December 31, 2025, +11.8% from the year before. It reported about 57,000 employees. Jim Davis is Chairman, CEO and President.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.0B 10-K, 2026-02-26 | $9.9B 10-K, 2026-02-26 | $9.3B 10-K, 2026-02-26 | $9.9B 10-K, 2025-02-20 | $10.8B 10-K, 2024-02-22 |
| Operating income | $1.6B 10-K, 2026-02-26 | $1.3B 10-K, 2026-02-26 | $1.3B 10-K, 2026-02-26 | $1.4B 10-K, 2025-02-20 | $2.4B 10-K, 2024-02-22 |
| SG&A | $2.0B 10-K, 2026-02-26 | $1.8B 10-K, 2026-02-26 | $1.6B 10-K, 2026-02-26 | $1.9B 10-K, 2025-02-20 | $1.7B 10-K, 2024-02-22 |
| Net income | $992M 10-K, 2026-02-26 | $871M 10-K, 2026-02-26 | $854M 10-K, 2026-02-26 | $946M 10-K, 2025-02-20 | $2.0B 10-K, 2024-02-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jim Davis | Chairman, CEO and President | 8-K, 2026-10-22 |
| J. E. Davis | CEO and President | 4, 2026-09-03 |
| Sam Samad | Executive Vice President & CFO | 4, 2026-07-27 |
| Sam A. Samad Chief Financial Officer, Quest Diagnostics | Executive Vice President and Chief Financial Officer | 10-K, 2026-02-26 |
| Mark E. Delaney Senior Vice President and Chief Commercial Officer | SVP & Chief Commercial Officer | 4, 2026-07-29 |
| Catherine T. Doherty | Executive Vice President | 4, 2026-03-06 |
| Subu Ramachandran | SVP, Regional Businesses | 3, 2026-11-05 |
 Michael E. Prevoznik SVP and General Counsel at Quest Diagnostics Incorporated | SVP & General Counsel | 4, 2026-08-31 |
 Karthik Kuppusamy | SVP, Clinical Solutions | 4, 2026-07-27 |
 Patrick Plewman Experienced Life Sciences Executive | SVP for Diagnostic Services | 4, 2026-07-27 |
| Michael J. Deppe SVP Corporate Controller & CAO at Quest Diagnostics | SVP, Corp. Controller & CAO | 4, 2026-03-06 |
What Quest Diagnostics Inc does
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 110.0 million (as of October 15, 2026) | 10-Q, October 23, 2026 |
|---|---|---|
| Public float | $20.0B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 23, 2026 |
| Latest proxy statement | Meeting May 20, 2026 (filed April 6, 2026) | DEF 14A, April 6, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 3, 2026 | Catherine T. Doherty Executive Vice President | Sale | 22,105 | $5.5M | Form 4, November 5, 2026 |
| October 26, 2026 | Gary M. Pfeiffer Director | Sale | 1,203 | $292K | Form 4, October 28, 2026 |
| September 1, 2026 | J. E. Davis CEO and President | Sale | 10,000 | $2.4M | Form 4, September 3, 2026 |
| August 28, 2026 | Michael E. Prevoznik SVP & General Counsel | Sale | 22,677 | $5.5M | Form 4, August 31, 2026 |
| July 28, 2026 | Mark E. Delaney SVP & Chief Commercial Officer | Sale | 1,600 | $376K | Form 4, July 29, 2026 |
| June 4, 2026 | Karthik Kuppusamy SVP, Clinical Solutions | Sale | 8,147 | $1.6M | Form 4, June 8, 2026 |
| June 1, 2026 | J. E. Davis CEO and President | Sale | 10,000 | $1.9M | Form 4, June 2, 2026 |
| March 5, 2026 | Catherine T. Doherty EVP, Regional Businesses | Sale | 5,558 | $1.1M | Form 4, March 6, 2026 |
Recent 8-K events
- 8-K filed 2026-10-22
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-22
- Item 8.01 Other events
- 8-K filed 2026-10-06
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-23
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-21
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-08
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-05-01
- Item 8.01 Other events
- 8-K filed 2026-04-21
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-12
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-10
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
Frequently asked questions about Quest Diagnostics Inc
- What does Quest Diagnostics Inc do?
- In its own words, from Item 1 of its 10-K: "Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management."
- What is Quest Diagnostics Inc's revenue?
- $11.0B for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Quest Diagnostics Inc profitable?
- Quest Diagnostics Inc reported net income of $992M for the fiscal year ending December 31, 2025.
- How many employees does Quest Diagnostics Inc have?
- About 57,000 as of February 26, 2026, as stated in its annual report.
- Who is the CEO of Quest Diagnostics Inc?
- Jim Davis, Chairman, CEO and President, as named in a 8-K filed October 22, 2026.
- Who is the CFO of Quest Diagnostics Inc?
- Sam Samad, Executive Vice President & CFO, as named in a 4 filed July 27, 2026.
- Where is Quest Diagnostics Inc headquartered?
- Secaucus, NJ.
- What is Quest Diagnostics Inc's stock ticker?
- DGX on NYSE.
- What industry is Quest Diagnostics Inc in?
- Services-Medical Laboratories, SIC code 8071.
- What is Quest Diagnostics Inc's website?
- questdiagnostics.com. Investor relations: https://ir.questdiagnostics.com/overview/default.aspx.
- When does Quest Diagnostics Inc report earnings next?
- January 21, 2027. Source: estimate_8k_pattern.
- Is Quest Diagnostics Inc a public company?
- Yes. Quest Diagnostics Inc files with the SEC under CIK 0001022079 and trades as DGX.
- Who audits Quest Diagnostics Inc?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many shares of Quest Diagnostics Inc are outstanding?
- 110.0 million shares as of October 15, 2026, from its 10-Q filed October 23, 2026.
- What is Quest Diagnostics Inc's public float?
- $20.0B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Quest Diagnostics Inc report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 23, 2026.
- When is Quest Diagnostics Inc's annual shareholder meeting?
- May 20, 2026, per its proxy statement (DEF 14A) filed April 6, 2026.
- Have Quest Diagnostics Inc insiders traded stock recently?
- Since July 31, 2025, officers and directors reported 31 open-market sales worth about $52.7M and 0 purchases on Forms 4 and 5. The most recent: Catherine T. Doherty (Executive Vice President) sold 22,105 shares on November 3, 2026.